Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Oil Prices Drop as Strait of Hormuz Shipping Recovers 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
CDC Confirms U.S. Ebola Case Linked to Congo Outbreak as Travel Restrictions Tighten 
Oil Prices Drop as Middle East Supply Recovery Eases Market Concerns 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Supreme Court Blocks 5th Circuit Ruling on Abortion Pill Access 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
U.S. Dollar Reaches One-Year High as Tech Sell-Off and Fed Rate Hike Expectations Support Demand 
Gold Drops Below $4,000 as Strong US Dollar and Fed Rate Hike Expectations Pressure Bullion 
Lotte Biologics Co. will invest $48 million into its Syracuse, New York, plant to upgrade and boost its production capacity for drugs and antibody-drug conjugates.
The South Korean company purchased the factory from Bristol Myers Squibb for $160 million last year as part of its strategy to go overseas.
Lotte Biologics will hire some 70 new workers as part of plans to expand its facilities.
The Syracuse plant can annually produce 35,000 liters of drug substances.
Lotte Biologics has been beefing up its production capacity and plans to invest $3 billion to build a bio-industrial complex in South Korea by 2030, to post $3 billion in revenue.
